Health

  • Recommend
  • Tweet
  • Print
  • Email

The Health Section develops policy positions that promote biomedical innovation and represent the best interests of BIO member companies with a direct interest in human health. Among the priority issues the Health Section focuses on are matters affecting the healthcare-related regulatory and reimbursement climate, pandemic and biodefense preparedness, publicly-funded scientific research, and personalized medicine. The Health Section is managed by a Section governing body and recommends members to sit on BIO's Board of Directors.
Staff Contact: Kay Holcombe

Ron Cohen, MD, Chair
Acorda Therapeutics, Inc
 
Paul J. Hastings, Vice Chair
OncoMed Pharmaceuticals, Inc
 
Rachel K. King, Immediate Past Chair
GlycoMimetics, Inc
 
Kristine Peterson, Secretary
Valeritas, Inc
 
Mark Alles
Celgene Corporation
 
Daniel Apel
Bayer Healthcare LLC
 
Stuart A. Arbuckle
Vertex Pharmaceuticals Incorporated
 
Alex M. Azar II
Eli Lilly and Company
 
Martin Babler
Principia Biopharma
 
Jean-Jacques Bienaimé
BioMarin Pharmaceutical, Inc
 
Chris Boerner
Bristol-Myers Squibb
 
Ian T. Clark
Genentech Roche Group
 
Stanley T. Crooke, MD, PhD
Ionis Pharmaceuticals, Inc.
 
John F. Crowley, JD, MBA
Amicus Therapeutics, Inc
 
Douglas A. Doerfler
MaxCyte, Inc
 
Deborah Dunsire, MD
FORUM Pharmaceuticals Inc
 
Paul R. Eisenberg, MD, MPH
Amgen, Inc.
 
Mark Enyedy
Shire
 
William Fitzsimmons, PharmD, MS
Astellas Pharma US
 
Julie L. Gerberding, MD, MPH
Merck & Co, Inc
 
John Glasspool
Baxalta
 
Glenn Gormley, MD, PhD
Daiichi Sankyo Pharma Development
 
Maxine Gowen, PhD
Trevena, Inc.
 
Peter S. Greenleaf
Sucampo Pharmaceuticals, Inc
 
David Hallal
Alexion Pharmaceuticals, Inc
 
Jeffrey Hatfield
Vitae Pharmaceuticals
 
Russell H. Herndon
Hydra Biosciences, Inc
 
Hervé Hoppenot
Incyte Corporation
 
Daniel M. Junius
ImmunoGen, Inc
 
Scott Koenig, MD, PhD
MacroGenics, Inc
 
Nick Leschly
bluebird bio
 
Elizabeth Lewis
Takeda Pharmaceuticals
 
Sabine Luik, MD, MPH
Boehringer Ingelheim Pharmaceuticals, Inc.
 
John Maraganore, PhD
Alnylam Pharmaceuticals, Inc
 
Thomas P. Mathers
CoLucid Pharmaceuticals, Inc
 
David P. Meeker, MD
Genzyme Corporation, A Sanofi Company
 
Steven J. Mento, PhD
Conatus Pharmaceuticals, Inc
 
John F. Milligan, PhD
Gilead Sciences, Inc
 
Michael Narachi
Orexigen Therapeutics, Inc
 
John A. Orwin
Relypsa, Inc
 
Adelene Q. Perkins
Infinity Pharmaceuticals, Inc.
 
Richard Pops
Alkermes, Inc.
 
Robert Repella
CSL Behring
 
Howard W. Robin
Nektar Therapeutics, Inc
 
David Schenkein, MD
Agios Pharmaceuticals, Inc
 
Michael Severino, MD
AbbVie Inc.
 
Christi L. Shaw
Novartis Pharmaceuticals Corporation
 
Jay P. Siegel, MD
Johnson & Johnson
 
Mark Skaletsky
Fenway Pharmaceuticals, Inc
 
Moncef Slaoui, PhD
GSK
 
David M. Stack
Pacira Pharmaceuticals, Inc.
 
Jean-Christophe Tellier
UCB, Inc.
 
Henri A. Termeer
AVEO Pharmaceuticals, Inc.
 
Mark Timney
Purdue Pharma LP
 
Gil Van Bokkelen, PhD
Athersys, Inc
 
Harold E. Van Wart, PhD
CymaBay Therapeutics
 
H. Thomas Watkins, Chair Emeritus
Biotechnology Innovation Organization
 
Allen Waxman
Eisai, Inc.
 
Edward Williams
Novo Nordisk
 
Rick E. Winningham
Theravance Biopharma US, Inc.
 
Gary Zieziula
EMD Serono, Inc
Hide Date: 
Hide Date
Hide Add This: 
Show